DE2935709C2 - Aminosäurelösung zur Behandlung von an Krebs erkrankten Personen - Google Patents

Aminosäurelösung zur Behandlung von an Krebs erkrankten Personen

Info

Publication number
DE2935709C2
DE2935709C2 DE2935709A DE2935709A DE2935709C2 DE 2935709 C2 DE2935709 C2 DE 2935709C2 DE 2935709 A DE2935709 A DE 2935709A DE 2935709 A DE2935709 A DE 2935709A DE 2935709 C2 DE2935709 C2 DE 2935709C2
Authority
DE
Germany
Prior art keywords
cancer
amino acid
day
mmc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2935709A
Other languages
German (de)
English (en)
Other versions
DE2935709A1 (de
Inventor
Koji Naruto Tokushima Ozeki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Factory Inc
Publication of DE2935709A1 publication Critical patent/DE2935709A1/de
Application granted granted Critical
Publication of DE2935709C2 publication Critical patent/DE2935709C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2935709A 1978-09-04 1979-09-04 Aminosäurelösung zur Behandlung von an Krebs erkrankten Personen Expired DE2935709C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10874978A JPS5535049A (en) 1978-09-04 1978-09-04 Amino acid transfusion for cancerous patient

Publications (2)

Publication Number Publication Date
DE2935709A1 DE2935709A1 (de) 1980-03-13
DE2935709C2 true DE2935709C2 (de) 1986-02-06

Family

ID=14492527

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2935709A Expired DE2935709C2 (de) 1978-09-04 1979-09-04 Aminosäurelösung zur Behandlung von an Krebs erkrankten Personen

Country Status (10)

Country Link
JP (1) JPS5535049A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU526207B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1134275A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH642541A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2935709C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2434622A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2029220B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1194844B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL190266C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE448679B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003552A1 (en) * 1981-04-17 1982-10-28 Hospital Supply Corp American Improved solution for parenteral nutrition
FR2508797B1 (fr) * 1981-07-03 1986-03-14 Charles Chany Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique
DE3329253A1 (de) * 1983-08-12 1985-02-21 Milupa Ag, 6382 Friedrichsdorf Verwendung eines aminosaeuregemisches zur bekaempfung insbesondere von lymphadenomen
HU191598B (en) * 1984-03-20 1987-03-30 Egyt Gyogyszervegyeszeti Gyar Method for the preparation of injection solution suitable preferably against cathosis
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
IL77629A (en) * 1985-01-22 1989-07-31 Abbott Lab High fat,low carbohydrate enteral nutritional for mula
FR2591893B1 (fr) * 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US5162373A (en) * 1986-01-17 1992-11-10 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
GB8917660D0 (en) * 1989-08-02 1989-09-20 Rana Ashok S J Prophylaxis of transurethral resection reactions
US5658895A (en) * 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
KR0172193B1 (ko) * 1991-10-07 1999-02-01 오오쓰까 아끼히꼬 암 치료용 경장제제
DE4228897A1 (de) * 1992-08-29 1994-03-03 Wella Ag Mittel zur Festigung der Haare auf der Basis von Lignin oder Ligninderivaten sowie Dihydroxypropyllignin
AU687768B2 (en) * 1992-11-19 1998-03-05 Anticancer, Inc. Use of methioninase as an antitumor agent in anti-methionine chemotherapy
HU213677B (en) * 1993-11-09 1997-12-29 Immunal Kft Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
RU2125874C1 (ru) * 1994-07-04 1999-02-10 Казанский государственный университет им.В.И.Ульянова-Ленина Композиция аминокислот с микроэлементами, обладающая противоопухолевой и антигипоксической активностью
WO1998004255A1 (en) * 1996-07-30 1998-02-05 Novartis Nutrition Ag Amino acid composition and use thereof in treating tumor growth and metastasis
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
RU2144821C1 (ru) * 1999-02-16 2000-01-27 Товарищество с ограниченной ответственностью Фирма "ГЛЕС" Противоопухолевое средство
EP1163904B1 (en) * 2000-06-16 2006-04-19 Rath, Matthias, Dr. med. Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
CH694549A5 (de) 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
US6686340B2 (en) 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
SG106614A1 (en) * 2001-06-21 2004-10-29 Matthias Rath Dr Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
JPWO2003030890A1 (ja) * 2001-10-05 2005-02-10 哲朗 浅尾 免疫系活性化剤
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005092097A1 (en) * 2004-03-19 2005-10-06 Pro-Pharmaceuticals, Inc. Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
WO2007016954A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing drug or alcohol induced breast cancer risk
WO2007016951A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced pancreatic cancer
WO2007016950A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced neurodegenerative disease
PL1909600T3 (pl) * 2005-07-29 2012-09-28 Tima Found Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem
WO2007016953A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing alcohol induced liver cancer risk
WO2007016952A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer
WO2007016949A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced neuropathy
US8211700B2 (en) 2007-03-28 2012-07-03 University Of Southern California Induction of differential stress resistance and uses thereof
US8865646B2 (en) 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
CA2722365C (en) 2008-04-24 2019-08-06 University Of Southern California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
KR101919747B1 (ko) * 2011-02-17 2018-11-20 각꼬호우진 구루메 다이가쿠 화학요법제의 항종양 활성 증강제
JP2016117702A (ja) * 2014-12-22 2016-06-30 武輝 山田 ガン細胞の死滅法
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT297935B (de) * 1968-05-09 1972-04-10 Astra Ab Verfahren zur Herstellung einer Infusionslösung von essentiellen Aminosäuren zur intravenösen Zufuhr bei urämischen Zuständen
SU423304A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1970-03-10 1974-04-05 Тейзо Хигаси, Дзинносуке Лбе, Теруо Таке, Сусуми Ватанабе , Масару Отани
DE2013026C3 (de) * 1970-03-19 1981-01-29 Wagner, Karl-Heinz, Prof. Dr.Med.Habil., 6300 Giessen Mittel zur Behandlung und Verhütung von Leberkrankheiten und muskulärer Insuffizienz
DE2530246A1 (de) * 1975-07-07 1977-01-13 Fresenius Chem Pharm Ind L-aminosaeuregemische fuer parenterale oder orale anwendung
DE2531204C2 (de) * 1975-07-12 1987-01-22 Fresenius AG, 6380 Bad Homburg L-Aminosäuregemische für die parenterale oder orale Ernährung

Also Published As

Publication number Publication date
JPS6154007B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-11-20
GB2029220A (en) 1980-03-19
IT7905216A0 (it) 1979-09-03
AU5036879A (en) 1980-03-13
DE2935709A1 (de) 1980-03-13
NL190266C (nl) 1994-01-03
GB2029220B (en) 1983-03-30
IT1194844B (it) 1988-09-28
CA1134275A (en) 1982-10-26
SE448679B (sv) 1987-03-16
JPS5535049A (en) 1980-03-11
CH642541A5 (de) 1984-04-30
FR2434622A1 (fr) 1980-03-28
NL7906620A (nl) 1980-03-06
NL190266B (nl) 1993-08-02
FR2434622B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1983-04-15
SE7907316L (sv) 1980-03-05
AU526207B2 (en) 1982-12-23

Similar Documents

Publication Publication Date Title
DE2935709C2 (de) Aminosäurelösung zur Behandlung von an Krebs erkrankten Personen
DE60308810T2 (de) Anregung der in-vivo synthese von proteinen mit zusammensetzungen enthaltend leucin
DE3302008C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2556100C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE69804281T2 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Leberkrankheiten
DE60118172T2 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
DE69814834T2 (de) Ernährungszusammensetzung zur verbesserung der zellenenergie
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE602004004817T2 (de) Myo-inositol hexaphosphat zur topischen verwendung
DE2310791A1 (de) Diaetmischungen zur behandlung des uebergewichtes bei menschen
CH653891A5 (de) Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier.
DE69127087T2 (de) Wachstumsfaktor und glutamin enthaltendes produkt und verwendung des wachstumsfaktors zur behandlung der darmschleimhaut
DE3650620T2 (de) Behandlungsverfahren kataboler dysfunktion
DE3040780C2 (de) Verwendung einer pharmazeutischen Zusammensetzung zur Behandlung von Diabetes
DE2921852A1 (de) Lipide senkendes mittel
DE69021415T2 (de) Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen.
DE69023989T2 (de) Verwendung von Vitamin B6 zur Verminderung von hohem Serotoninspiegel.
DE69318061T2 (de) Zubereitung enthaltend L-Carnitin oder Acyl-L-Carnitin in Kombination mit einem ACE-Inhibitor zur Behandlung von kardiovaskulären Störungen
DE1915798A1 (de) Arzneimittel gegen UEbersaeuerung
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE2712777A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
DE2335216A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
EP2001555A1 (de) Verwendung von strobilurinen zur behandlung von störungen des eisen-stoffwechsels
DE2516027A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
DE69426986T2 (de) Behandlung von laminitis

Legal Events

Date Code Title Description
OD Request for examination
D2 Grant after examination
8328 Change in the person/name/address of the agent

Free format text: SOLF, A., DR.-ING., 8000 MUENCHEN ZAPF, C., DIPL.-ING., PAT.-ANW., 5600 WUPPERTAL

8364 No opposition during term of opposition